Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aadi Biosciences Inc (NQ: AADI )

8.060 +0.160 (+2.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 74,787
Open 8.010
Bid (Size) 7.350 (1)
Ask (Size) 8.400 (1)
Prev. Close 7.900
Today's Range 7.870 - 8.090
52wk Range 6.800 - 17.27
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: Aadi Bioscience Q1 Earnings
 
Via Benzinga
Earnings Preview For Aadi Bioscience
 
Via Benzinga

Performance

YTD
-34.52%
-34.52%
1 Month
+3.60%
+3.60%
3 Month
-8.51%
-8.51%
6 Month
-39.81%
-39.81%
1 Year
-51.33%
-51.33%

More News

Read More
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Aadi Bioscience: Q2 Earnings Insights
Via Benzinga
Aadi Bioscience: Q1 Earnings Insights
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Aadi Bioscience, Lowers Price Target To $48
Via Benzinga
Aadi Bioscience: Q4 Earnings Insights
Via Benzinga
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Via Benzinga
Exposures COVID-19 Product Safety
What 4 Analyst Ratings Have To Say About Aadi Bioscience
Via Benzinga
Aadi Bioscience Stock Pops On First-Ever FDA Approval In Rare Cancer
Via Investor's Business Daily
Exposures Product Safety
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Exposures COVID-19 Product Safety
Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
Via Benzinga
76 Biggest Movers From Yesterday
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.